sintilimab
eli lilly
['sintilimab', 'nsclc', 'lcsm,(-blcsm)', 'sclc']
neoscore neoadjuvant anti-pd1 sintilimab+chemo x 2 cycles vs 3 cycles in nsclc; mpr 26.9% vs 41.4%; pcr and mpr higher with 3 cycles, no increase in surgical risk/complications dr. fuming qiu #asco22 #lcsm 
Thoracic Med Onc @MUSChealth @muschollings Charleston, South Carolina. Former Heme/Onc fellow @MontefioreNYC @EinsteinMed